Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04673656 · ClinicalTrials.gov registry record · NA
Dose-Response Study to Evaluate the Effect of BKR-017 on Insulin Resistance and Other Metabolic Parameters in Type 2 Diabetes Patients
A NA study, sponsored by BioKier.
- Completed
- Registry status
- NA
- Development phase
- 60
- Enrollment target
NCT04673656 is a NA study that has completed, run by BioKier. The registered enrollment target is 60 participants.
The verdict
NCT04673656, a NA study, has completed, sponsored by BioKier.
- COMPLETED
- Registry status
- NA
- Development phase
- 60 participants
- Enrollment target
Study Summary
This study is a randomized, double-blind, placebo-controlled, dose-response study of BKR-017 and placebo that will be conducted at two investigative sites. The total duration of subject involvement is approximately 15 weeks; the screening period can be up to 3 weeks prior to the start of test period, followed by a 12-week test period. During the test period, subjects will self-administer three tablets of test product, two times daily: before breakfast and before bedtime.
Interventions
- DIETARY_SUPPLEMENT BKR-017
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2021-04-18 |
| Est. Completion | 2023-02-07 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04673656
The ClinicalTrials.gov registry entry for NCT04673656 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is BioKier, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which BKR-017 is the first listed.
NCT04673656 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04673656 about?
NCT04673656 is a clinical study titled "Dose-Response Study to Evaluate the Effect of BKR-017 on Insulin Resistance and Other Metabolic Parameters in Type 2 Diabetes Patients". This study is a randomized, double-blind, placebo-controlled, dose-response study of BKR-017 and placebo that will be conducted at two investigative sites. The total duration of subject involvement is approximately 15 weeks; the screening period can be up to 3 weeks prior to the start of test period...
What is the current status of trial NCT04673656?
This trial is currently completed. It is a NA study. The enrollment target is 60 participants. The study started on 2021-04-18. Estimated completion is 2023-02-07.
What interventions are being tested in trial NCT04673656?
The interventions under investigation include: BKR-017 (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT04673656?
This trial is sponsored by BioKier, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.